EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial

Alastair J S Webb iD, Jacqueline S Birks iD, Karolina A Feakins iD, Amy Lawson, Jesse Dawson iD, Alexander M K Rothman iD, David J Werring iD, Osian Llwyd iD, Catriona R Stewart iD, James Thomas

Circulation Research · 05.07.2024 · 135 (2) · 320-331

DOI: 10.1161/circresaha.124.324327 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation Research, erschienen am 05.07.2024. Verfasst von Alastair J S Webb und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Centre for Prevention of Stroke and Dementia (A.J.S.W., K.A.F., A.L., O.L., C.R.S., J.T.), University of Oxford, United Kingdom. Hauptthemen laut MEDLINE: Sildenafil Citrate, Cerebral Small Vessel Diseases, Cerebrovascular Circulation, Cross-Over Studies. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Alzheimer's Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascular cognitive impairment due to cerebral small vessel disease is associated with cerebral pulsatility, white matter hypoperfusion, and reduced cerebrovascular reactivity (CVR), and is potentially improved by endothelium-targeted drugs such as cilostazol. Whether sildenafil, a phosphodiesterase-5 inhibitor, improves cerebrovascular dysfunction is unknown. METHODS: OxHARP trial (Oxford Haemodynamic Adaptation to Reduce Pulsatility) was a double-blind, randomized, placebo-controlled, 3-way crossover trial after nonembolic cerebrovascular events with mild-moderate white matter hyperintensities (WMH), the most prevalent manifestation of cerebral small vessel disease. The primary outcome assessed the superiority of 3 weeks of sildenafil 50 mg thrice daily versus placebo (mixed-effect linear models) on middle cerebral artery pulsatility, derived from peak systolic and end-diastolic velocities (transcranial ultrasound), with noninferiority to cilostazol 100 mg twice daily. Secondary end points included the following: cerebrovascular reactivity during inhalation of air, 4% and 6% CO 2 on transcranial ultrasound (transcranial ultrasound-CVR); blood oxygen-level dependent–magnetic resonance imaging within WMH (CVR-WMH) and normal-appearing white matter (CVR-normal-appearing white matter); cerebral perfusion by arterial spin labeling (magnetic resonance imaging pseudocontinuous arterial spin labeling); and resistance by cerebrovascular conductance. Adverse effects were compared by Cochran Q. RESULTS: In 65/75 (87%) patients (median, 70 years;79% male) with valid primary outcome data, cerebral pulsatility was unchanged on sildenafil versus placebo (0.02, −0.01 to 0.05; P =0.18), or versus cilostazol (−0.01, −0.04 to 0.02; P =0.36), despite increased blood flow (∆ peak systolic velocity, 6.3 cm/s, 3.5–9.07; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sildenafil CitrateCerebral Small Vessel DiseasesCerebrovascular CirculationCross-Over StudiesHumansMaleFemaleAgedDouble-Blind MethodMiddle AgedCilostazolPhosphodiesterase 5 InhibitorsTreatment OutcomePulsatile FlowMagnetic Resonance ImagingMiddle Cerebral Artery

Stichwörter der Autor:innen

cerebral small vessel diseasescilostazolperfusionwhite matter

Substanzen

Sildenafil CitrateCilostazolPhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Wolfson Centre for Prevention of Stroke and Dementia (A.J.S.W., K.A.F., A.L., O.L., C.R.S., J.T.), University of Oxford, United Kingdom.
  • Department of Brain Sciences, Imperial College London, United Kingdom (A.J.S.W.).
  • Centre for Statistics in Medicine, Botnar Research Centre (J.S.B.), University of Oxford, United Kingdom.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom (J.D.).
  • Department of Cardiovascular Science, University of Sheffield, United Kingdom (A.M.K.R.).
  • Research Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, United Kingdom (D.J.W.).

ORCID-Profile: Alastair J S Webb, Jacqueline S Birks, Karolina A Feakins, Jesse Dawson, Alexander M K Rothman, David J Werring, Osian Llwyd, Catriona R Stewart

Förderung

  • Wellcome Trust
  • Alzheimer's Society

Zitieren

APA

Webb, A. J. S., Birks, J. S., Feakins, K. A., Lawson, A., Dawson, J., Rothman, A. M. K., Werring, D. J., Llwyd, O., Stewart, C. R., & Thomas, J. (2024). Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial. Circulation Research, 135(2), 320-331. https://doi.org/10.1161/circresaha.124.324327

Vancouver

Webb AJS, Birks JS, Feakins KA, Lawson A, Dawson J, Rothman AMK, et al. Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial. Circulation Research. 2024;135(2):320-331. doi:10.1161/circresaha.124.324327

BibTeX
@article{Webb2024,
  author = {Webb, Alastair J S and Birks, Jacqueline S and Feakins, Karolina A and Lawson, Amy and Dawson, Jesse and Rothman, Alexander M K and Werring, David J and Llwyd, Osian and Stewart, Catriona R and Thomas, James},
  title = {Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial},
  journal = {Circulation Research},
  year = {2024},
  volume = {135},
  number = {2},
  pages = {320--331},
  doi = {10.1161/circresaha.124.324327}
}
Kostenlos starten →